The metabolic syndrome: Risk factors and management

Journal of Cardiovascular Nursing

Volumn 21, Issue 4, 2006, Pages 306-313

  Cassells, Holly B ^a   Haffner, Steven M ^b  

^a UNIVERSITY OF THE INCARNATE WORD   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cardiovascular disease; Metabolic syndrome; Obesity; Type 2 diabetes; Weight loss

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; SIMVASTATIN;

DIABETIC ANGIOPATHY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEALTH BEHAVIOR; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING; REVIEW; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GLUCOSE TOLERANCE TEST; HEALTH BEHAVIOR; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; RISK FACTORS; SIMVASTATIN;

EID: 33748653130     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200607000-00012     Document Type: Review

References (49)

1. Kannel WB. Diabetes and cardiovascular disease. The Framingham Study. JAMA. 1979;241:2035-2038.
2. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
3. Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small dense LDL) in men. Circulation. 2000;102:179-184.
4. Pouliot MC, Després JP, Nadeau A, et al. Visceral obesity in men: associations with glucose tolerance, plasma insulin and lipoprotein levels. Diabetes. 1992;41:826-834.
5. Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460-468.
6. Ferrannini E, Haffner SM, Mitchell BD, et al. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416-422.
7. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-3421.
8. Deedwania PC. Clinical significance of cardiovascular dysmetabolic syndrome. Curr Control Trials Cardiovasc Med. 2002;3:1-5.
9. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149:1514-1520.
10. Reaven G. Syndrome X: 10 years after. Drugs. 1999;58(suppl 1):19-20.
11. Tchernof A, Lamarche B, Prud'Homme D, et al. The dense LDL phenotype: associations with plasma lipoprotein levels, visceral obesity and hyperinsulinemia in men. Diabetes Care. 1996;19:629-637.
12. Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
13. Festa A, D'Agostino R, Mykkänen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol. 1999;19:562-568.
14. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.
15. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization; 1999. Available at: http://whqlibdoc.who.int/hq/1999/ WHO_NCD_NCS_99.2.pdf. Accessed June 20, 2004.
16. Einhorn D, Reaven GM, Cobbin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237-252.
17. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant D, for the Conference Participants. Definition of metabolic syndrome: report of the National, Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
18. Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA, for Conference Participants. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on scientific issues related to management. Circulation. 2004;109:551-556.
19. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
20. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among U.S. adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-359.
21. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP metabolic syndrome, diabetes mellitus and prevalence of coronary heart disease. Diabetes. 2003;52:1210-1214.
22. Sinha R, Fisch G, Teague WV, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002;346:802-808.
23. Kaufman FR. Type 2 diabetes mellitus in children and youth: a new epidemic. J Pediatr Endocrinol Metab. 2002;15(suppl 2):737-744.
24. McGill HC, McMahan A, Herderick EE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 2002;105:2712-2718.
25. Weiss R, Dzuira J, Burgert WV, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362-2374.
26. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
27. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
28. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation. 2004;109:1955-1959.
29. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes. 2002;51:1131-1137.
30. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:391-397.
31. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109:2818-2825.
32. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. NEJM. 1998;339:229-234.
33. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
34. Lakka HM, Laaksonen DE, Tuomilehtho J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002:2709-2716.
35. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129-1134.
36. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070-1077.
37. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care. 2003;26:3153-3159.
38. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002;136:575-581.
39. Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
40. Tuomilehto J, Lindström J, Eriksson JG, et al for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among patients with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
41. Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 1998;229:12-20.
42. Chiasson J-L, Josse RG, Gomis R, et al for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 2002;359:2072-2077.
43. Buchanan TA, Xianag AH, Peters RK, et al. Preservation of pancreatic Q-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk Hispanic women. Diabetes. 2002;51:2796-2803.
44. Chiasson J-L, Josse RG, Gomis R, Hannefeld M, Karasik A, Laakso M, for the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA. 2003;290:486-494.
45. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analysis in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999;159:2661-2667.
46. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events Trial. Circulation. 1998;98:2513-2519.
47. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104:3046-3051.
48. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention study. Circulation. 2003;108:414-419.
49. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.